Search results
Results from the WOW.Com Content Network
ONX-0801 (BGC 945) is an experimental drug that has been developed to target ovarian cancer. [1] It is a folate receptor alpha mediated thymidylate synthase inhibitor. [2] [3] ONX-0801 was originally developed by BTG and the Institute of Cancer Research in the UK, and subsequently licensed to Onyx Pharmaceuticals for clinical
Annwen Jones, chief executive at Target Ovarian Cancer, said: “Early diagnosis of ovarian cancer is vital, and we are pleased to see this research demonstrate that there are more accurate ways ...
Ovarian cancer is a cancerous tumor of an ovary. [10] It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. [3] [11] The ovary is made up of three different cell types including epithelial cells, germ cells, and stromal cells. [12]
Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells. Many targeted therapies are examples of immunotherapy (using immune mechanisms for therapeutic goals) developed by the field of cancer immunology. Thus, as immunomodulators, they are one type of biological response modifiers.
Ovarian cancer is a type of cancer which begins in the ovaries. Anyone with ovaries can get it, including women, trans men, non-binary people and intersex people. [2] Although ovarian cancer is much less frequent, it is the deadliest among gynecologic cancers. [3] Early signs of possible breast cancer
For premium support please call: 800-290-4726 more ways to reach us
As ovarian cancer is rarely symptomatic until an advanced stage, [42] regular pre-emptive screening is a particularly important tool for avoiding the late stage at which most patients present. However, A 2011 US study found that transvaginal ultrasound and cancer marker CA125 screening did not reduce ovarian cancer mortality. [43]
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [2] [5] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. [5] [6]